Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer
Key Points
Key Points
- This guideline focuses on patients with advanced, recurrent, or metastatic prostate cancer and noncastrate testosterone levels whose disease is not yet castration-resistant, including those with biochemical recurrence only.
- The future of noncastrate advanced, recurrent, or metastatic prostate cancer care is predicted to include highly personalized treatment plans based on advanced genetic testing, next generation imaging, and the availability of highly predictive biomarkers.
- This targeted update is driven by results from recent Phase III clinical trials (ARASENS, PEACE-1, ENZAMET, and ARCHES) and two recent meta-analyses.
Treatment
Treatment
...ial Treatment...
...endation 1.0(Updated) Docetaxel, abiratero...
...DROGEN DEPRIVATION THERAPY (ADT) PLUS DOCETAXEL...
...tion 1.1(Updated) For patients with me...
...commendation 1.11(New) For patients...
...commendation 1.15(New) For patients wi...
Recommendation 1.16(New) The recommended regi...
...mmendation 1.2(Updated) For patients with low-vo...
...ecommendation 1.3(Updated) For patien...
ADT PLUS ABIRATERONE
...endation 1.4For patients with high-risk de novo...
...1.5For patients with low-risk de novo...
...commendation 1.6The recommended regimen...
...S ENZALUTAMIDE...
...ion 1.7(Updated) ADT plus enzalutamide should...
...tion 1.8(Updated) The recommended regi...
...DT PLUS APALUT...
...mendation 1.9ADT plus apalutamide should also...
...dation 1.95(Updated) The recommended regimen for p...
...nation Therapies...
....1ADT plus abiraterone and prednisolone sho...
...mendation 2.2In resource-constraine...
...y Androgen Deprivation...
...ommendation 3.1Early (immediate) ADT may b...
...rmittent Androgen Deprivatio...
...ion 4.1Intermittent therapy may be of...
...1. Initial Management of Noncastrate Metastatic Pr...